EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy

Shayan Smani iD, Vinaik Sundaresan, Soum D Lokeshwar, Ankur U Choksi, Jeffrey Carbonella, Joseph Brito, Joseph Renzulli, Preston Sprenkle iD, Michael S Leapman

Exploration of Targeted Anti-tumor Therapy · 30.07.2024 · 5 (5) · 981-996

DOI: 10.37349/etat.2024.00259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Exploration of Targeted Anti-tumor Therapy, online erschienen am 30.07.2024. Verfasst von Shayan Smani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT 06520, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate identification of prostate cancer Gleason grade group remains an important component of the initial management of clinically localized disease. However, Gleason score upgrading (GSU) from biopsy to radical prostatectomy can occur in up to a third of patients treated with surgery. Concern for disease undergrading remains a source of diagnostic uncertainty, contributing to both over-treatment of low-risk disease as well as under-treatment of higher-risk prostate cancer. This review examines the published literature concerning risk factors for GSU from time of biopsy to prostatectomy final pathology. Risk factors identified for Gleason upgrading include patient demographic and clinical factors including age, body mass index, race, prostate volume, and biomarker based assays, including prostate-specific antigen (PSA) density, and testosterone values. In addition, prostate magnetic resonance imaging (MRI) findings have also been associated with GSU. Biopsy-specific characteristics associated with GSU include lower number of biopsy cores and lack of targeted methodology, and possibly increasing percent biopsy core positivity. Recognition of risk factors for disease undergrading may prompt confirmatory testing including repeat sampling or imaging. Continued refinements in imaging guided biopsy techniques may also reduce sampling error contributing to undergrading.

Schlagwörter

Stichwörter der Autor:innen

Gleason score upgradingProstate cancerconcordancemagnetic resonance imaging fusion biopsyprostate-specific antigen

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, CT 06520, USA.
  • Department of Urology, Yale School of Medicine, New Haven, CT 06520, USA.

ORCID-Profile: Shayan Smani, Preston Sprenkle

Förderung

  • NIA NIH HHS

Zitieren

APA

Smani, S., Sundaresan, V., Lokeshwar, S. D., Choksi, A. U., Carbonella, J., Brito, J., Renzulli, J., Sprenkle, P., & Leapman, M. S. (2024). Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration of Targeted Anti-tumor Therapy, 5(5), 981-996. https://doi.org/10.37349/etat.2024.00259

Vancouver

Smani S, Sundaresan V, Lokeshwar SD, Choksi AU, Carbonella J, Brito J, et al. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration of Targeted Anti-tumor Therapy. 2024;5(5):981-996. doi:10.37349/etat.2024.00259

BibTeX
@article{Smani2024,
  author = {Smani, Shayan and Sundaresan, Vinaik and Lokeshwar, Soum D and Choksi, Ankur U and Carbonella, Jeffrey and Brito, Joseph and Renzulli, Joseph and Sprenkle, Preston and Leapman, Michael S},
  title = {Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy},
  journal = {Exploration of Targeted Anti-tumor Therapy},
  year = {2024},
  volume = {5},
  number = {5},
  pages = {981--996},
  doi = {10.37349/etat.2024.00259}
}
Kostenlos starten →